There's Plenty Of Good Science Out There: An Interview With AstraZeneca's Andrew Hughes (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
VC investors are starting to adopt a more big pharma mentality of waiting until a molecule really has proved itself before they put their money up, Hughes, AstraZeneca's global early development director for oncology, says.
You may also be interested in...
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
How To Pick A Winner In Oncology: An Interview With AstraZeneca's Andrew Hughes (Part 1 of 2)
In the contest to predict early winners in the pipeline game, the challenge of this decade is predictive efficacy, according to Hughes.